Indeed, PD-L1 IHC with the 22C3 antibody was the first US Food and Drug Administration (FDA)-approved biomarker for use with pembrolizumab for non-small cell lung cancer (NSCLC).14 This evidence concerns the gene CD274 and non-small cell lung carcinoma.